UK-based biotechnology company Retrogenix and US-based Resonant Therapeutics, Inc. announced today that they have entered into a non-exclusive strategic partnership to identify the targets of Resonant antibodies directed against the tumor microenvironment.
Resonant exploits its proprietary IMPaCT tumor microenvironment models and data platform to discover novel, unappreciated targets and functionally active anti-tumor antibodies for difficult to treat tumors.
By recapitulating the tumor microenvironment and using a live-cell, function-first approach, Resonant’s platform generates therapeutic candidates that would not be discovered by other methods with unprecedented speed. The target screening performed by Retrogenix will focus on hundreds of novel, prioritized antibodies in Resonant’s collection.
Targets within the tumor microenvironment may include both plasma membrane proteins as well as proteins typically secreted into the extracellular space. Retrogenix’s extensive library of human proteins make it uniquely placed for assessing candidate antibodies for target binding.
Jo Soden, Co-managing Director of Retrogenix, said: “We look forward working with Resonant to deconvolute the targets for their antibodies. Resonant’s innovative platform is delivering functional therapeutic candidates at rapid pace and we welcome the opportunity to identify the specific, biologically-relevant targets which will help progress these leads towards promising new therapies for patients with cancer.”
Dr. John K. Westwick, CEO of Resonant, added: “Resonant has created a platform for rapid generation of novel anti-tumor antibody candidates. Our previous work with Retrogenix validated their technology as a uniquely powerful approach for antibody target deconvolution, and we look forward to working with Retrogenix to enhance our growing pipeline of antibody candidates.”
Source: Company Press Release